Ad
The vaccines developed by Pfizer/BioNTech and Moderna use 'new messenger RNA' (mRNA) technology to trigger an immune response (Photo: Arne Müseler)

EU to buy 1.8bn BioNTech jabs, in switch to mRNA vaccines

The European Commission president Ursula von der Leyen on Wednesday (14 April) announced the bloc has entered negotiations to buy 1.8 billion doses of the Pfizer/BioNtech vaccine - to be delivered between now and 2023.

She also confirmed that member states will receive, starting this month, 50 million additional Pfizer/BioNtech Covid-19 vaccines, as doses initially expected at the end of 2021 were brought forward to the second quarter.

In total, the company will supply the EU wit...

Get EU news that matters

Back our independent journalism by becoming a supporting member

Already a member? Login here

Author Bio

Elena is EUobserver's Managing Editor. She is from Spain and has studied journalism and new media in Spanish and Belgian universities. Previously she worked on European affairs at VoteWatch Europe and the Spanish news agency EFE.

The vaccines developed by Pfizer/BioNTech and Moderna use 'new messenger RNA' (mRNA) technology to trigger an immune response (Photo: Arne Müseler)

Tags

Author Bio

Elena is EUobserver's Managing Editor. She is from Spain and has studied journalism and new media in Spanish and Belgian universities. Previously she worked on European affairs at VoteWatch Europe and the Spanish news agency EFE.

Ad

Related articles

Ad
Ad